Coagulation factorV and thrombophilia:: Background and mechanisms

被引:124
作者
Segers, Kenneth
Dahlback, Bjorn
Nicolaes, Gerry A. F. [1 ]
机构
[1] Maastricht Univ, Cardiovasc Res Inst Maastricht, Dept Biochem, Maastricht, Netherlands
[2] Lund Univ, Univ Hosp, Wallenberg Lab, Dept Lab Med, Malmo, Sweden
关键词
factorV; coagulation; thrombosis; thrombophilia; protein C pathway;
D O I
10.1160/TH07-02-0150
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Human coagulation factorV (FV) is an essential coagulation protein with functions in both the pro- and anticoagulant pathways. Failure to express and control FV functions can either lead to bleeding, or to thromboembolic disease. Both events may develop into a life-threatening condition. Since the first description of APC resistance, and in particular the description of the so-called factorV(Leiden) mutation, in which a prominent activated protein C cleavage site in FV has been abolished through a mutation in the FV gene,FV has been in the center of attention of thrombosis research. In this review we describe ow the functions of FV are expressed and regulated and provide an extensive description of the role that FV plays in the etiology of thromboembolic disease.
引用
收藏
页码:530 / 542
页数:13
相关论文
共 161 条
[1]   The crystal structure of activated protein C-inactivated bovine factor Va: Implications for cofactor function [J].
Adams, TE ;
Hockin, MF ;
Mann, KG ;
Everse, SJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (24) :8918-8923
[2]   Inherited defects of coagulation factor V: the hemorrhagic side [J].
Asselta, R ;
Tenchini, ML ;
Duga, S .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2006, 4 (01) :26-34
[3]   Proposed structural models of the prothrombinase (FXa-FVa) complex [J].
Autin, L ;
Steen, M ;
Dahlbäck, B ;
Villoutreix, BO .
PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS, 2006, 63 (03) :440-450
[4]   Regulation of extrinsic pathway factor Xa formation by tissue factor pathway inhibitor [J].
Baugh, RJ ;
Broze, GJ ;
Krishnaswamy, S .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (08) :4378-4386
[5]   Efficacy and safety of recombinant human activated protein C for severe sepsis. [J].
Bernard, GR ;
Vincent, JL ;
Laterre, P ;
LaRosa, SP ;
Dhainaut, JF ;
Lopez-Rodriguez, A ;
Steingrub, JS ;
Garber, GE ;
Helterbrand, JD ;
Ely, EW ;
Fisher, CJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (10) :699-709
[6]   A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype [J].
Bernardi, F ;
Faioni, EM ;
Castoldi, E ;
Lunghi, B ;
Castaman, G ;
Sacchi, E ;
Mannucci, PM .
BLOOD, 1997, 90 (04) :1552-1557
[7]   MUTATION IN BLOOD-COAGULATION FACTOR-V ASSOCIATED WITH RESISTANCE TO ACTIVATED PROTEIN-C [J].
BERTINA, RM ;
KOELEMAN, BPC ;
KOSTER, T ;
ROSENDAAL, FR ;
DIRVEN, RJ ;
DERONDE, H ;
VANDERVELDEN, PA ;
REITSMA, PH .
NATURE, 1994, 369 (6475) :64-67
[8]   Regions remote from the site of cleavage determine macromolecular substrate recognition by the prothrombinase complex [J].
Betz, A ;
Krishnaswamy, S .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (17) :10709-10718
[9]   Complement inhibitor C4b-binding protein -: friend or foe in the innate immune system? [J].
Blom, AM ;
Villoutreix, BO ;
Dahlbäck, B .
MOLECULAR IMMUNOLOGY, 2004, 40 (18) :1333-1346
[10]   Active site-independent recognition of substrates and product by bovine prothrombinase - A fluorescence resonance energy transfer study [J].
Boskovic, DS ;
Troxler, T ;
Krishnaswamy, S .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (20) :20786-20793